Research of Exenatide for Overweight/Obese PCOS Patients With IGR

NCT03352869 on ClinicalTrials.gov · last registry update 2019-09-11

An unusually large phase 4: 183 participants, more than double the 75 typical for the stage. The sponsor logged completion for 1 July 2018. Primary outcome, as filed: Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation. exenatide is approved in the US, but not for obesity and pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: RenJi Hospital
Sponsor type: Other
Enrollment: 183
Started: 2017-11-28
Primary completion: 2018-07-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation

Conditions studied

Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.